WELCOME TO TROVE THERAPEUTICS
At Trove Therapeutics, we are developing a novel therapeutic protein platform with a lead product called Therabron™ to address an underlying cause of targeted respiratory conditions. Trove is a privately held, clinical-stage, biopharmaceutical company. Therabron™ is based on a naturally occurring secretoglobin protein called SCGB1A1, CC10, CC16, CCSP, or uteroglobin, which is a potent anti-inflammatory, immunomodulatory, homeostatic agent. Trove is developing three distinct products using different formulations of Therabron™ with different routes of administration for specific respiratory diseases impacting people from childhood through adulthood.
Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native SCGB1A1 protein in patients. We are developing a pharmaceutical therapy to replace SCGB1A1 with the synthetic version (Therabron™) in respiratory diseases characterized by inflammation and pre-existing SCGB1A1 deficiency.
Secretoglobins are naturally occurring proteins produced in the body by Club Cells. They are some of the most abundant proteins secreted in the airways. Naturally occurring SCGB1A1 is the most abundant protein in the fluid that lines the respiratory tract in both the upper and lower lung, including the sinus cavities. Unlike many treatments that provide symptomatic treatment only, Therabron™ has the potential to address underlying disease processes, resolve inflammation, and accelerate airway repair in respiratory conditions like persistent sinusitis, asthma, COPD, bronchiolitis obliterans (a type of pulmonary fibrosis), and acute lung injuries due to severe influenza-like illness and smoke inhalation.
